Literature DB >> 12842799

The Rorschach Ego Impairment Index: prediction of treatment outcome in a child psychiatric population.

John M Stokes1, David L Pogge, Jennifer Powell-Lunder, Alfred W Ward, Lale Bilginer, Victoria A DeLuca.   

Abstract

In this study, we investigated the treatment utility of the revision of Perry and Viglione's (1991) Rorschach Ego Impairment Index (EII-2) in a sample of 53 child psychiatric inpatients. Parent ratings of symptomatic functioning on the Devereux Scales of Mental Disorders (DSMD; Naglieri, LeBuffe, & Pfeiffer, 1994) were obtained at admission, 30 days postdischarge, and 120 days postdischarge. EII-2 scores correlated with initial symptom elevations on the Critical Pathology at admission. EII-2 scores did not predict short-term response to treatment. However, EII-2 scores demonstrated moderate correlations with long-term outcome and relapse. EII-2 was related to prediction of worsening of symptoms between 30-day and 120-day follow-up as measured by Reliable Change Index scores that were computed for the Externalizing, Internalizing, Critical Pathology, and Total DSMD scales.

Entities:  

Mesh:

Year:  2003        PMID: 12842799     DOI: 10.1207/S15327752JPA8101_02

Source DB:  PubMed          Journal:  J Pers Assess        ISSN: 0022-3891


  3 in total

1.  Predicting response to intensive multimodal inpatient treatment: a comparison of single- and multiple-class growth modeling approaches.

Authors:  Justin D Smith; Mark J Van Ryzin; J Christopher Fowler; Leonard Handler
Journal:  J Pers Assess       Date:  2013-09-25

2.  Ego Impairment Index (EII-2) as a predictor of outcome in short- and long-term psychotherapy during a 5-year follow-up.

Authors:  Jaakko Stenius; Erkki Heinonen; Olavi Lindfors; Juha Holma; Paul Knekt
Journal:  J Clin Psychol       Date:  2022-02-28

3.  Relationship of Pretreatment Rorschach Factors to Symptoms, Quality of Life, and Real-Life Functioning in a 3-Year Follow-Up of Traumatized Refugee Patients.

Authors:  Marianne Opaas; Ellen Hartmann; Tore Wentzel-Larsen; Sverre Varvin
Journal:  J Pers Assess       Date:  2015-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.